Lijuan Wu

Title: Lijuan Wu: Innovator in Anti-Tumor Drug Development

Introduction

Lijuan Wu is a notable inventor based in Shandong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor drugs. With a total of 2 patents, his work focuses on innovative approaches to cancer treatment.

Latest Patents

One of Lijuan Wu's latest patents is titled "Use of Tegaserod in Preparation of Anti-Tumor Drug." This patent discloses the use of Tegaserod or a pharmaceutically acceptable salt thereof as a JAK-STAT3 signaling pathway inhibitor and an immunomodulator in the preparation of an anti-tumor drug. The findings indicate that Tegaserod and its salts exhibit excellent inhibitory effects on the growth of various tumor cells both in vivo and in vitro, making them promising candidates for cancer treatment. Another significant patent is "Application of Glucan in Preparation of Drug." This patent describes the use of a β-1,3/1,6-glucan in the preparation of a pharmaceutical composition or formulation. This composition can enhance the antitumor effects of immunotherapy, radiotherapy, or chemotherapy, and is particularly useful for treating leukopenia and/or thrombocytopenia.

Career Highlights

Lijuan Wu has worked with reputable organizations such as the Marine Biomedical Research Institute of Qingdao and Qingdao Conson Pharmaceutical Co., Ltd. His experience in these institutions has contributed to his expertise in pharmaceutical research and development.

Collaborations

Throughout his career, Lijuan Wu has collaborated with notable colleagues, including Jinbo Yang and Qiaoling Song. These collaborations have likely enriched his research and innovation efforts in the pharmaceutical field.

Conclusion

Lijuan Wu's contributions to the development of anti-tumor drugs highlight his innovative spirit and dedication to improving cancer treatment. His patents reflect a commitment to advancing medical science and enhancing patient care.